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Objective: The authors report three cases of neuroleptic malignant syndrome (NMS) induced 
by atypical antipsychotics (olanzapine and clozapine) which showed classic features of NMS 
including muscular rigidity and prominent fever.
Method: Case reports.
Results: A 66-year-old man with dementia and alcohol abuse developed NMS while on 
olanzapine for agitation and combativeness. A 62-year-old man with schizophrenia developed 
NMS 6 days after starting clozapine. A 43-year-old man with bipolar disorder developed NMS 
14 days after starting clozapine. All three cases showed classic features of NMS including 
muscular rigidity and fever. Resolution of fever and muscular rigidity occurred within 72 hours 
with discontinuation of neuroleptics, supportive care, and lorazepam. The NMS rating scale 
reﬂ  ected daily clinical improvement.
Conclusion: Classic NMS characterized by muscular rigidity and prominent fever may occur 
with atypical neuroleptics. Our cases suggest recovery from NMS associated with atypical 
neuroleptics may be hastened by lorazepam, as was previously reported for NMS from typical 
neuroleptics. Also, the NMS rating scale was sensitive to clinical improvement.
Keywords: atypical antipsychotics, neuroleptic malignant syndrome, lorazepam, catatonia, 
rating scale
Introduction
Neuroleptic malignant syndrome (NMS) is a rare but potentially life-threatening 
adverse reaction to antipsychotic drugs and other dopamine-modulating agents 
(Caroff and Mann 1993). The syndrome is characterized by motor, behavioral, auto-
nomic, and laboratory abnormalities (Caroff et al 1993; Francis et al 2000). Several 
clinical and research diagnostic criteria for NMS are available. Most require muscular 
rigidity and fever (Caroff et al 1993; APA 1994) but some permit a diagnosis without 
rigidity (eg, Levenson 1985).
Almost all typical neuroleptics have been associated with NMS (Caroff et al 1993). 
Some workers predicted that atypical neuroleptics would not cause NMS since intense 
dopaminergic blockade is one hypothesized basis for NMS. However, numerous cases 
of apparent NMS related to atypical neuroleptics have been reported (Caroff et al 2000, 
2003), and most of these are associated with muscular rigidity and fever. In one review, 
however, 20% of reported cases of clozapine-related NMS lacked muscle rigidity as 
part of clinical picture (Caroff et al 2000).
We report three cases of NMS related to atypical neuroleptics (olanzapine and 
clozapine). All had classic features of NMS, including fever and muscle rigidity and 
met both APA (1994) and Caroff-Mann (1993) criteria. Lorazepam appeared to be Neuropsychiatric Disease and Treatment 2006:2(2) 236
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beneﬁ  cial in hastening recovery. In all three cases, the NMS 
rating scale showed improvement in all four clinical domains 
(motor, behavioral, autonomic, and laboratory).
NMS rating scale
The NMS rating scale (Yacoub et al 2004; Appendix) 
includes 23 items encompassing motor, behavioral, auto-
nomic, and laboratory domains of NMS. In conjunction with 
the present report, reliability was determined using records 
from 10 well-deﬁ  ned cases of NMS (Francis et al 2000). 
All cases met APA (1994) or Caroff-Mann (1993) criteria 
on the day of presentation. Two independent raters deter-
mined scores at presentation and on the third and ﬁ  fth day 
of treatment, yielding 30 pairs of ratings. Overall reliability 
was high (r = 0.99 for total score and r = 0.98 for number of 
signs present; range of scores 0–53, range of signs 0–16). The 
kappa statistic for agreement (presence/absence) averaged 
0.85 (range 0.59–1.00) for all 23 items. The Cronbach alpha 
statistic was 0.48 calculated from 19 of 23 scale items which 
were present in  20% of cases.
Case 1
A 66-year-old white male with a history of dementia and 
alcohol abuse was hospitalized for increased aggressive 
behavior. He had no prior psychiatric admissions. On the 
day of admission after he sustained a fall, a CT scan of 
brain showed subarachnoid hemorrhage at the right supe-
rior sulcus and possible hemorrhagic contusion at the left 
frontal lobe. Over the course of hospitalization, he had serial 
CT scans to observe resolution of the hemorrhage. He was 
started on olanzapine for intermittent periods of agitation 
and combativeness. Olanzapine was titrated to 7.5 mg daily. 
Ten days after initiation of olanzapine, he became abruptly 
somnolent with body temperature 39.7ºC (rectal) and severe 
muscle rigidity in both upper and lower extremities. He had 
severe diaphoresis and ﬂ  uctuation of blood pressure and 
pulse. Laboratory values showed elevation of white blood 
cells (WBC) (14800 K/L), elevation of creatine phospho-
sphkinase (CPK) 2800 U/L (normal   174 U/L), and mild 
elevation in serum alanine aminotransferase and aspartate 
aminotransferase. Brain CT showed resolution of the previ-
ous subarachnoid hemorrhage and no new cerebrovascular 
abnormalities. An MRI of the brain was unremarkable, as 
were CSF studies and chest X-ray. Blood, urine, and spu-
tum cultures showed no growth in 48 hours. A presumptive 
diagnosis of NMS was made. Olanzapine was immediately 
discontinued and supportive care initiated (IV hydration and 
as-needed acetaminophen). The NMS rating scale showed 
44 on the ﬁ  rst day. Intravenous lorazepam was given as 
needed every 4 hours for behavioral agitation along with 
a ﬁ  xed 0.5 mg intravenous push twice daily. He received 
a total of 8.5 mg lorazepam in the ﬁ  rst 24 hours and 3 mg 
lorazepam in the next day. Fever and muscular rigidity 
resolved within 48 hours. All other NMS manifestations 
resolved in 9 days (Figure 1, Case 1). He was not rechal-
lenged with neuroleptic medication. He was discharged 
to a nursing home in stable condition on lorazepam 2 mg, 
divaloproex sodium 2000 mg, and trazodone 300 mg (daily 
doses).
Case 2
A 62-year-old man with a history of schizophrenia was 
admitted to the hospital for worsening of paranoid ide-
ation, non-commanding auditory hallucinations, and 
agitation. For years, he had been on various neuroleptics 
with partial response. Prior to this hospitalization, he 
was partially stable on thiothixene but adherence to this 
medication was questionable. On admission, he was tak-
ing thiothixene and benztropine. Within few days, the 
dose of thiothixene was increased to 15 mg daily. He 
became less agitated but was paranoid and had bizarre 
ideas (“I feel a razor cutting me up”). Gradually, thio-
thixene and benztropine were discontinued and clozapine 
started. Clozapine was titrated to 100 mg daily. By the 
sixth day, he became febrile (38.1ºC oral) with increased 
muscular rigidity of both upper extremities. He was con-
fused and had urinary incontinence. Laboratory studies 
showed CPK of 412 U/L and WBC of 7.6 K/L. Blood and 
urinary cultures were negative and the chest X ray was 
unremarkable. During the first 24 hours, he had tremors 
in both upper extremities and autonomic instability with 
diaphoresis and fluctuation of blood pressure and pulse. 
A presumptive diagnosis of NMS was made. The initial 
NMS rating scale score was 27. Clozapine was discon-
tinued, and supportive care initiated (oral hydration and 
as_needed acetaminophen). During the first two days, 
he received lorazepam 3 mg daily. On the third day, he 
received a total of 6 mg lorazepam and remained on this 
dose for a week. Gradually, lorazepam was tapered to 3 mg 
daily. Muscular rigidity and fever abated within 72 hours 
after onset of NMS. All other features of NMS resolved 
on the fifth day (Figure 1, Case 2). He was rechallenged 
with quetiapine two weeks after the resolution of NMS 
without recurrence of symptoms. He was discharged from 
the hospital in stable condition on quetiapine 200 mg and 
lorazepam 2 mg (daily doses).Neuropsychiatric Disease and Treatment 2006:2(2) 237
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Case 3
A 43-year-old man with a history of bipolar disorder was 
hospitalized for manic symptoms with psychotic features. 
Upon admission to the hospital, he was taking daily doses 
of perphenazine 8 mg, divaloproex sodium 2000 mg, and 
aripriprazole 20 mg. During the hospitalization, aripripra-
zole was discontinued and perphenazine titrated to 48 mg 
in divided doses. Divaloproex sodium was increased to 
3000 mg but later decreased to 1750 mg for excessive seda-
tion and fatigue. He was maintained on these medications 
with minimal response, showing paranoid delusions and 
periods of agitated behavior. Perphenazine was gradually 
discontinued. Clozapine was started and titrated up to 
175 mg daily. Fourteen days after initiation of clozapine, 
he developed fever 38.3ºC (oral) with rigidity of both upper 
extremities. He was confused with ﬂ  uctuating orientation 
and sensorium, and showed diaphoresis and tachypnea. 
His blood pressure was stable, his gait was unsteady, and 
he had an unwitnessed fall. A head CT scan showed mild 
cortical atrophy. Urine and blood cultures were negative 
as was the chest X-ray. CPK was 312 U/L, WBC were 
12800 K/L, serum iron level decreased to 16 μg/dL (normal 
range 30–160 μg/dL), and transaminases remained normal. 
A clinical diagnosis of NMS was made. Both clozapine and 
divaloproex sodium were discontinued and intravenous 
ﬂ  uids started. During the ﬁ  rst day of NMS, he received 
2 mg lorazepam intramuscularly for severe agitation. 
The NMS rating scale score was 27. He received total of 
6 mg lorazepam on the second day and 8 mg on the third 
day. From day 4, he was on lorazepam 6 mg daily for 5 more 
days, then it was gradually discontinued. Within 72 hours 
of NMS onset, both fever and muscular rigidity resolved. 
All other NMS features resolved in 9 days (Figure 1, 
Case 3). He was discharged from the hospital in stable 
condition 12 days after the onset of NMS on divaloproex 
sodium 2000 mg daily. He was not rechallenged with any 
neuroleptic medication.
Discussion
Our three cases with atypical neuroleptics (clozapine and 
olanzapine) demonstrated classic presentations of NMS, 
which met Levenson (1985), APA (1994), and Caroff-Mann 
(1993) criteria. In Case 2, cessation of benztropine may have 
promoted NMS as well. Each case showed prominent fever 
and muscular rigidity as well as a variety of behavioral, 
autonomic, and laboratory abnormalities. In each case, 
NMS remitted rapidly with cessation of the antipsychotic 
followed by supportive care. Lorazepam was administered 
in all cases, which may have hastened recovery as has been 
reported for NMS due to typical neuroleptics (Francis et al 
2000; Khaldarov 2000).
In a review of NMS cases associated with atypical 
neuroleptics, Sachdev et al (1995) concluded that NMS 
















































Figure 1 Neuroleptic malignant syndrome (NMS) scale scores (z) and daily dose of lorazepam () in patients with NMS.Neuropsychiatric Disease and Treatment 2006:2(2) 238
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CPK elevation. Caroff et al (2000) reviewed all NMS cases 
published related to atypical neuroleptics, and applied various 
diagnostic criteria sets retrospectively. They concluded that 
although all NMS cases associated with atypical antipsychot-
ics met broad criteria for NMS, some patients present only 
with a partial or incomplete form of classic NMS such as 
lack of rigidity, fever, or other primary features. Neverthe-
less, they found most published cases of NMS associated 
with olanzapine and clozapine included prominent muscular 
rigidity.
The standard approach to manage NMS includes 
recognizing the diagnosis early, excluding alternative causes 
of the symptoms, discontinuing suspected triggering drugs, 
and providing supportive care to reduce temperature, ensure 
ﬂ  uid balance, and prevent complications (Caroff 2003). 
There is limited consensus and inconsistent evidence on the 
comparative efﬁ  cacy of speciﬁ  c treatments for NMS. Davis 
et al (2000) concluded that, in view of heterogeneity of cases 
diagnosed as NMS, lack of prospective, controlled trials, and 
standardized dosing, it is difﬁ  cult to consider any speciﬁ  c 
pharmacological intervention or electroconvulsive therapy 
(ECT) to be superior.
Benzodiazepines have been recommended for managing 
agitation and reversing catatonic symptoms of NMS (Fink 
1996). In some cases, benzodiazepines were found to be 
effective when other medications failed (Miyaoko 1997). 
Some workers have advocated benzodiazepines as speciﬁ  c 
treatments for NMS, based on clinical similarities between 
catatonia and NMS (Fink 1996; Davis et al 2000; Francis 
et al 2000). Francis el at (2000) reported robust resolution 
of NMS symptoms with high potency benzodiazepines in 
16 patients meeting APA (1994) or Caroff-Mann (1993) 
criteria whose NMS was precipitated by typical antipsychotic 
agents. Muscular rigidity and fever abated in 24–48 hours 
with lorazepam at daily doses of ∼3 mg. Khaldarov (2000) 
reported two additional cases of NMS from typical anti-
psychotics that appeared to respond similarly to lorazepam 
treatment with prompt resolution of NMS. In the present 
three cases, NMS was precipitated by atypical neuroleptic 
agents. We employed a similar management in our three 
patients, using supportive care and lorazepam. Both fever 
and muscular rigidity improved and resolved in 24–72 hours. 
These ﬁ  ndings indicate that lorazepam may be useful for 
management of NMS precipitated by both typical and atypi-
cal antipsychotic agents.
A review of the literature showed several diagnostic 
criteria for NMS. All encompass a combination of motor, 
behavioral, autonomic, and laboratory domains. One prior 
attempt to construct a scale for NMS included only one item 
in each domain (Hynes and Victar 1996). Yacoub et al (2004) 
designed an NMS rating scale (Appendix) to aid recognition 
and quantify the severity and clinical course of NMS once a 
diagnosis has been established. The scale includes 23 items 
with anchored scoring according to presence, absence, or 
severity. The scale assesses 5 motor, 2 behavioral, 10 auto-
nomic, and 6 laboratory domains of NMS, and was found 
to be of high reliability. The Francis-Yacoub NMS rating 
scale was applied to all three cases from day one to day 
seven, and the scores reﬂ  ected rapid clinical improvement 
(Figure 1).
Further research and clinical data are needed in terms 
of risk factors, nosological issues, and more effective and 
speciﬁ  c treatment options of NMS.
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Appendix: Francis-Yacoub NMS Rating Scale
•   This scale is designed to rate the severity of neuroleptic malignant 
syndrome [NMS] and should not be used for diagnosis. The diagnosis 
of NMS can be made by a variety of criteria including the APA [1994] 
and Caroff-Mann [1993]. Patients considered for a diagnosis of NMS 
are typically quite ill and other etiologies of fever and autonomic 
disturbance should be sought concurrently.
•   Ratings can be made at regular intervals, eg, daily or q8 hours; express 
results as score obtained/scored items
•  Rate peak observation or most extreme value for interval
•  Interpolate laboratory values as appropriate
0.  [Not scored] Proper Pharmacological Setting:
History of administration of oral neuroleptics 7 days prior to onset [4 
weeks for depot formulations] or other agents associated with NMS, 
eg, cessation of dopamine agonists, adjustments in antiparkinsonian 
medications, etc.
Yes. Specify agent, dosage, and route of administration
No.   Pursue alternative explanations for rigidity, fever, autonomic signs, 
etc. May complete scale pending further history.
1.  Extrapyramidal features: rigidity of extremities
Preferably examined on passive motion of large joints while patient 
relaxes in sitting posture [lying posture acceptable].
0 Absent
1   Minimal or found only with distraction by patient moving other 
limbs
2  Mild to moderate
3  Marked, full range of motion can be obtained
4  Severe, restricted range of motion, or “lead pipe”
2.  Extrapyramidal features: rigidity of neck and/or upper 
trunk
Examined as per extremities. Upper trunk examined by [passive and 
active] ﬂ  exion.
0 Absent
1  Minimal or only with distraction by patient moving limbs
2  Mild to moderate
3  Marked, but full range of motion obtained
4  Severe, restricted range of motion, or “lead pipe”
3.  Extrapyramidal features: pharyngeal/swallowing
Rate by observation or reports from interval of evaluation.
0 Normal
1  Rare disturbed swallowing or choking episodes
2  Occasional disturbed swallowing or choking episodes
3  Dietary change required, eg, soft food
4  Tube or gastrostomy feedings required
4.  Extrapyramidal features: pharyngeal/speech
Rate by observation or reports from interval of evaluation. Rate “0” if 
mute or intubated.
0 Normal
1   Mildly affected. No difﬁ  culty being understood; slight loss of 
expression, clarity, or loudness
2   Moderately affected. Slurred or monotonous, or must repeat some 
statements; can communicate
4   Severely affected. Frequently must repeat statements or impaired 
ability to communicate
5.  Extrapyramidal features: tremors at rest
Observe limbs, trunk, and head. Note and rate region of highest severity.
0 Absent
1  Slight: low amplitude or intermittent
2  Moderate: persistent; easily noticeable, bothers patient
3  Marked: prominent, disrupts some activities
4  Severe: disrupts most activities
6.  Consciousness/mental status changes
Attempt to engage in conversation and assess orientation.
0   Normal, full consciousness/oriented to time, person and place; 
normal verbal communication
4   Delirium [ﬂ  uctuation of consciousness or orientation], or somnolent/
drowsy, or oriented to 1–2 out of 3
8  Coma or complete disorientation
7. Catatonia
Observe and elicit catatonic signs, preferably using Bush-Francis 
Catatonia Scale. Alternatively, assess for DSM-IV catatonic signs other 
than rigidity: immobility, catalepsy, waxy ﬂ  exibility, excitement, negativism, 
mutism, posturing, stereotypy, mannerisms, grimacing, and echopraxia/
echolalia. At least 2 signs deﬁ  ne presence of catatonia.
0 absent
8 present
8. Body  temperature
Oral measurement is convenient, but rectal measurement more closely 
reﬂ  ects the core body temperature. Rectal temperature is ∼0.5 C higher 
than oral. Rate peak value in interval of evaluation.
0    37.0ºC [98.6 ºF] [Rectal   37.5ºC]
4    37.0 and   37.5ºC [98.6–99.5 ºF] [Rectal   37.5 and   38ºC]
8    37.5 and   39ºC [99.5–102.2 ºF] [Rectal   38 and   39.5ºC]
12    39ºC and   40ºC [102.2–104 ºF] [Rectal   39.5ºC and   40.5ºC]
16    40ºC [104 ºF] [Rectal   40.5ºC]
9. Systolic  blood  pressure
Record peak value during interval being rated.
0    140 mmHg
1    140 and   160
2    160 and   180
4    180
10.  Diastolic blood pressure
Record peak value during interval being rated.
0    90 mmHg
1    90 and   100
2    100 and   110
4    110
11. Pulse
Record peak value during interval being rated.
0    90/min
1    90 and  100
2    100 and  120
4    120Neuropsychiatric Disease and Treatment 2006:2(2) 240
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12.  Labile blood pressure [systolic or diastolic]
Record difference between peak and lowest values during interval being 
rated, for both systolic and diastolic. Record larger value.
0  +/– 10 mmHg
1  +/– 20
2  +/– 30
4  +/– 40 or greater
13. Labile  pulse
Record difference between peak and lowest values during interval being 
rated.
0  +/– 10/min
1  +/– 20
2  +/– 30
4  +/– 40 or more
14. Diaphoresis




4  Prominent or bedding/clothing moist
15. Respiration
Ask for subjective complaints, or observe respiration.
0  No dyspnea, normal respiration
2  Shortness of breath or tachypnea [rate   20] with minimal exertion 
[eg, talking]
4  Shortness of breath or tachypnea [rate   20] at rest or accessory 
respiratory muscle use
8  Supplemental oxygen or ventilator use even if intermittent
16. Dehydration
Evidence of dehydration based on clinical or laboratory examination.
0 Absent
2  [A] Poor skin turgor and/or [B] dry skin; normal laboratory values
4   [A] or [B] with laboratory evidence of dehydration, eg, increased 
serum BUN [blood urea nitrogen]/creatinine ratio   20, increased 
hematocrit, increased urine osmolality, urine sodium   20 mEq/L, 
weight loss   0.25 kg/day, etc.
17. Incontinence
Urinary or fecal incontinence in the period of rating. If urinary catheter 
in use, rate “0.”
0 Absent
2 One  episode
4  More than one episode
18. Serum  CPK
Record peak value. If not repeated, record most recent. Values based on 
normal   200 IU/L. Adjust for local normal value
0 Normal
1  200–500 [2.5 x normal]
2  501–1000 [5 x normal]
3  1001–5000 [25 x normal]
4  More than 5000
19. WBC
Record peak value. If not repeated, record most recent measurement.
0 Normal  [  11000]
4    11000 and   15000
8    15000
20.  Serum transaminase (AST or ALT)
Record peak value. If not repeated, record most recent measurement. 
Values based on normal   50 IU/L. Adjust for local normal value. 
Rate “0” if pre-existing liver disease.
0 Normal  [  50]
1  51–125 [2.5 x normal]
2  126–250 [5 x normal]
3  251–1250 [25 x normal]
4    1250 [ 25 x normal]
21. Serum  iron  level
Laboratory values based on local normal.
0 normal
2 decreased  levels
22. Myoglobinemia/myoglobinuria
Laboratory evidence of muscle breakdown
0  Absent or normal
4  Present or elevated
23. Acid-base balance
Laboratory evidence of acid/base disturbance. Metabolic acidosis is likely 
to be the most common ﬁ  nding. Best determined with arterial blood 
gases [ABG].
0  Absent [normal pH, normal CO2, normal HCO3]
4   Present with compensation, or reduced HCO3 without ABG 
determination
8   Present, inadequate compensation [eg, metabolic acidosis with low 
pH]
Total Score ________________________
Date ________________________
Time  ________________________
Rater  ________________________